drugset / Trial / NCT01433913

Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery

NCT01433913 ↗

Phase 2 Completed 20 enrolled National Cancer Institute (NCI)
RandomizedParallel-groupDouble-blindTreatment

Summary

This randomized phase II trial studies how well metformin hydrochloride works compared to placebo in treating patients with prostate cancer undergoing surgery. Metformin hydrochloride may make some enzymes active. These enzymes may block other enzymes needed for cell growth and stop the growth of tumor cells.

Timeline

Start
2011-11
Primary completion
2014-04
Completion
2014-04

Outcome

Missed primary endpoint

registry Arm I (Metformin Hydrochloride) vs Arm II (Placebo); p = 0.23; Wilcoxon (Mann-Whitney) NCT01433913 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule — Oral